Premium
Pioglitazone promotes peripheral nerve remyelination after crush injury through CD36 upregulation
Author(s) -
Eto Masaki,
Sumi Hisae,
Fujimura Harutoshi,
Yoshikawa Hiroo,
Sakoda Saburo
Publication year - 2008
Publication title -
journal of the peripheral nervous system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 67
eISSN - 1529-8027
pISSN - 1085-9489
DOI - 10.1111/j.1529-8027.2008.00183.x
Subject(s) - remyelination , cd36 , medicine , sciatic nerve , nerve injury , crush injury , downregulation and upregulation , peripheral neuropathy , immunohistochemistry , pioglitazone , sural nerve , peripheral nerve injury , pathology , endocrinology , receptor , anesthesia , biology , surgery , central nervous system , myelin , type 2 diabetes , biochemistry , gene , diabetes mellitus
In our previous study, we found that CD36‐deficient mice showed significant delays in peripheral nerve remyelination after sciatic nerve crush injury and suggested that CD36 played an important role in the restoration of injured peripheral nerves. The aim of this study was to investigate whether CD36 upregulation can promote peripheral nerve remyelination. We made crush injury that caused demyelination and mild axonal degeneration to sciatic nerves and investigated the effect of pioglitazone (PIO) on the remyelination post‐injury in C57Bl/6 wild‐type and CD36‐deficient mice. The immunohistochemistry with anti‐CD36 antibody showed that CD36 was upregulated in macrophages infiltrating peripheral nerves from the wild‐type mice by PIO administration at 1 week post‐injury. The lectin histochemistry represented that infiltrating macrophages lessened in the wild‐type mice at 3 weeks post‐injury by PIO administration. General histopathology and morphometry indicated that thinly myelinated fibers and naked axons diminished in PIO‐treated wild‐type mice compared with non‐treated wild‐type mice at 3 weeks post‐injury. No significant differences were observed in remyelination and number of infiltrating macrophages between PIO‐treated and non‐treated CD36‐deficient mice. These results indicate that PIO promotes peripheral nerve remyelination possibly through CD36. It may be possible to apply PIO to the remedy against demyelinating neuropathies.